Global HER2-Negative Breast Cancer - Pipeline Insight, 2022

This “HER2-Negative Breast Cancer - Pipeline Insight, 2022” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

HER2-Negative Breast Cancer Understanding

HER2-Negative Breast Cancer: Overview

HER2-Negative Breast Cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and/or progesterone along with no expression of the human epidermal growth factor receptor 2 (HER2). Immunohistochemistry (IHC) test and/or Fluorescent in situ hybridization (FISH) is done to find out if cancer cells have estrogen and progesterone receptors. Common therapies for the treatment of HER2-Negative Breast Cancer include endocrine therapy (ET), ovarian suppression, aromatase inhibition, and/or CDK4/6 inhibitors.

"HER2-Negative Breast Cancer - Pipeline Insight, 2022" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HER2-Negative Breast Cancer pipeline landscape is provided which includes the disease overview and HER2-Negative Breast Cancer treatment guidelines. The assessment part of the report embraces, in depth HER2-Negative Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence HER2-Negative Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve HER2-Negative Breast Cancer.

HER2-Negative Breast Cancer Emerging Drugs Chapters

This segment of the HER2-Negative Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HER2-Negative Breast Cancer Emerging Drugs

Capivasertib + Fulvestrant: AstraZeneca

Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently in phase III clinical studies for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.

Dalpiciclib: Jiangsu HengRui

MedicineDalpiciclib (formerly SHR 6390) is an orally administered small molecule and selective cyclin-dependent kinase (CDK)-4/6 inhibitor. Dalpiciclib in Combination with Letrozole or Anastrozole or Fulvestrant is in Phase III clinical evaluation in patients with HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer.

HER2-Negative Breast Cancer: Therapeutic Assessment

This segment of the report provides insights about the different HER2-Negative Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in HER2-Negative Breast Cancer

There are approx. 85+ key companies which are developing the therapies for HER2-Negative Breast Cancer. The companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu HengRui Medicine.

Phases

This report covers around 85+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HER2-Negative Breast Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HER2-Negative Breast Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HER2-Negative Breast Cancer drugs.

HER2-Negative Breast Cancer Report Insights

• HER2-Negative Breast Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

HER2-Negative Breast Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing HER2-Negative Breast Cancer drugs?
• How many HER2-Negative Breast Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HER2-Negative Breast Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HER2-Negative Breast Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for HER2-Negative Breast Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• Laekna
• Novartis
• Jiangsu HengRui Medicine
• Roche
• Olema Pharmaceuticals
• Haihe Biopharma
• G1 Therapeutics
• Merck
• Chia Tai Tianqing Pharmaceutical
• Tyme
• Radius Pharmaceuticals
• H3 Biomedicine
• Eli Lilly and Company
• Eagle Pharmaceuticals

 

Key Products

• Capivasertib
• Afuresertib
• Dalpiciclib
• Inavolisib
• OP-1250
• CYH33
• Lerociclib
• Pembrolizumab
• TQB3616
• SM-88
• Elacestrant
• H3B-6545
• Fulvestrant

This product will be delivered within 1-3 business days.